Prime Capital Investment Advisors
EDIT icon

Prime Capital Investment Advisors’s Editas Medicine EDIT Stock Holding History

Prime Capital Investment Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.8K Sell
26,471
-640
-2% -$1.87K ﹤0.01% 1059
2026
Q1 		$67K Sell
27,111
-1,430
-5% -$3.03K ﹤0.01% 1014
2025
Q4 		$58.5K Sell
28,541
-678
-2% -$1.96K ﹤0.01% 1000
2025
Q3 		$101K Sell
29,219
-3,039
-9% -$8.48K ﹤0.01% 969
2025
Q2 		$71K Sell
32,258
-15,588
-33% -$25.5K ﹤0.01% 926
2025
Q1 		$55.5K Sell
47,846
-1,679
-3% -$2.47K ﹤0.01% 1024
2024
Q4 		$62.9K Buy
+49,525
New +$126K ﹤0.01% 910

Other funds holding EDIT

TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Prime Capital Investment Advisors's EDIT Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its Editas Medicine (EDIT) stake by 2.4% in Q2 2026, selling an estimated $1.87K and leaving 26,471 shares worth $85.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Prime Capital Investment Advisors first reported a position in EDIT in Q4 2024 and has held it in 7 quarters since. The position peaked at $101K in Q3 2025. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Prime Capital Investment Advisors held 26,471 shares of Editas Medicine worth $85.8K as of Q2 2026.
  • Prime Capital Investment Advisors sold 640 Editas Medicine shares in Q2 2026, an estimated $1.87K.
  • Editas Medicine made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #1059 holding.
  • Prime Capital Investment Advisors first reported a position in Editas Medicine in Q4 2024 and has held it in 7 quarters since.
  • Prime Capital Investment Advisors's Editas Medicine position peaked at $101K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.